亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

医学 甲状腺髓样癌 凡德他尼 卡波扎尼布 甲状腺癌 内科学 甲状腺 肿瘤科 队列 癌症 酪氨酸激酶 受体
作者
Vivek Subbiah,Mimi I. Hu,Lori J. Wirth,Martin Schüler,Aaron S. Mansfield,Giuseppe Curigliano,Marcia S. Brose,Viola W. Zhu,Sophie Leboulleux,Daniel W. Bowles,Christina S. Baik,Douglas Adkins,Bhumsuk Keam,Ignacio Matos,Elena Garralda,Justin F. Gainor,Gilberto Lopes,Chia‐Chi Lin,Yann Godbert,Debashis Sarker
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:9 (8): 491-501 被引量:348
标识
DOI:10.1016/s2213-8587(21)00120-0
摘要

Summary

Background

Oncogenic alterations in RET represent important therapeutic targets in thyroid cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent, selective RET inhibitor, in patients with RET-altered thyroid cancers.

Methods

ARROW, a phase 1/2, open-label study done in 13 countries across 71 sites in community and hospital settings, enrolled patients 18 years or older with RET-altered locally advanced or metastatic solid tumours, including RET-mutant medullary thyroid and RET fusion-positive thyroid cancers, and an Eastern Co-operative Oncology Group performance status of 0–2 (later limited to 0–1 in a protocol amendment). Phase 2 primary endpoints assessed for patients who received 400 mg once-daily oral pralsetinib until disease progression, intolerance, withdrawal of consent, or investigator decision, were overall response rate (Response Evaluation Criteria in Solid Tumours version 1.1; masked independent central review) and safety. Tumour response was assessed for patients with RET-mutant medullary thyroid cancer who had received previous cabozantinib or vandetanib, or both, or were ineligible for standard therapy and patients with previously treated RET fusion-positive thyroid cancer; safety was assessed for all patients with RET-altered thyroid cancer. This ongoing study is registered with clinicaltrials.gov, NCT03037385, and enrolment of patients with RET fusion-positive thyroid cancer was ongoing at the time of this interim analysis.

Findings

Between Mar 17, 2017, and May 22, 2020, 122 patients with RET-mutant medullary and 20 with RET fusion–positive thyroid cancers were enrolled. Among patients with baseline measurable disease who received pralsetinib by July 11, 2019 (enrolment cutoff for efficacy analysis), overall response rates were 15 (71%) of 21 (95% CI 48–89) in patients with treatment-naive RET-mutant medullary thyroid cancer and 33 (60%) of 55 (95% CI 46–73) in patients who had previously received cabozantinib or vandetanib, or both, and eight (89%) of nine (95% CI 52–100) in patients with RET fusion-positive thyroid cancer (all responses confirmed for each group). Common (≥10%) grade 3 and above treatment-related adverse events among patients with RET-altered thyroid cancer enrolled by May 22, 2020, were hypertension (24 patients [17%] of 142), neutropenia (19 [13%]), lymphopenia (17 [12%]), and anaemia (14 [10%]). Serious treatment-related adverse events were reported in 21 patients (15%), the most frequent (≥2%) of which was pneumonitis (five patients [4%]). Five patients [4%] discontinued owing to treatment-related events. One (1%) patient died owing to a treatment-related adverse event.

Interpretation

Pralsetinib is a new, well-tolerated, potent once-daily oral treatment option for patients with RET-altered thyroid cancer.

Funding

Blueprint Medicines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
希望天下0贩的0的应助被leo采纳,获得30
1秒前
初景的应助被Kyrie采纳,获得20
5秒前
忧郁思远完成签到,获得积分10
7秒前
10秒前
orixero的应助被科研通管家采纳,获得10
10秒前
10秒前
柳贯一发布了新的文献求助10
17秒前
20秒前
星野的应助被白华苍松采纳,获得10
24秒前
NA01UM10完成签到,获得积分10
25秒前
回家放羊完成签到 ,获得积分10
39秒前
40秒前
leo发布了新的文献求助30
43秒前
46秒前
fheu发布了新的文献求助10
50秒前
50秒前
感性的远航完成签到,获得积分10
52秒前
yc发布了新的文献求助10
53秒前
科研通AI65的应助被yc采纳,获得10
59秒前
平城落叶完成签到,获得积分10
1分钟前
顾矜的应助被leo采纳,获得10
1分钟前
Yanyu完成签到,获得积分10
1分钟前
suge完成签到,获得积分10
1分钟前
1分钟前
清脆世界完成签到 ,获得积分10
1分钟前
Hello的应助被fheu采纳,获得10
1分钟前
leo发布了新的文献求助10
1分钟前
1分钟前
Ava的应助被酷炫的尔蓉采纳,获得10
1分钟前
可爱的函函的应助被leo采纳,获得10
1分钟前
友好沛槐完成签到,获得积分10
1分钟前
Peiqi完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
fantasy的应助被科研通管家采纳,获得10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190078
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852047
捐赠科研通 7788239
什么是DOI,文献DOI怎么找? 3436240
关于科研通互助平台的介绍 2559964
邀请新用户注册赠送积分活动 2482824